Ortho Evra is the first transdermal (skin) patch approved for birth control. The weekly prescription patch releases norelgestromin (a progestin hormone), and ethinyl estradiol (an estrogen hormone), through the skin into the blood stream to prevent pregnancy. The U.S. Food and Drug Administration approved Ortho Evra, manufactured by Ortho McNeil, a subsidiary of Johnson & Johnson, in November 2001.
Ortho Evra, an alternative to birth control pills, is a one-and-three-quarter inch square patch consisting of three layers. The hormones are embedded in the adhesive layer and are slowly released when the patch is applied to the skin.
According to the FDA, women who choose to use the product should apply it to the lower abdomen, buttocks or upper body but not to the breasts. Each patch should be worn continuously for one week and should then be replaced with a new patch on the same day of the week for a total of three weeks of patch wear.
The fourth week, which is patch-free, allows a woman to have her menstrual period - similar to the regimen for birth control pills.
Like birth control pills, Ortho Evra is effective for prevention of pregnancy when used as directed. The risks of using this product are similar to the risks of using birth control pills including an increased risk of blood clots, heart attack, and stroke. The labeling also carries the warning that cigarette smoking increases the risk of serious cardiovascular side effects from use of combination hormonal contraceptives.
In April 2004, an 18-year-old New York fashion student died while using the Ortho Evra patch. According to officials for the FDA and Ortho McNeil, the death is the first linked to the contraceptive patch. Information from the Medical Examiner's Office indicates Zakiya Kennedy's death was caused by a blood clot.
In November 2005, Ortho McNeil issued a warning to millions of women revealing that the patch exposes them to significant amounts of estrogen and may put them at greater risk of developing blood clots.
Based on an internal company memo, Ortho McNeil refused to fund a study which would have compared the Ortho Evra patch to the company's Ortho-Cyclen birth control pill. The company was afraid that the results of such a study may not be positive for the patch. However, the company now states that it plans to conduct a study for the patch, similar to studies previously conducted with the Pill. The Ortho Evra website states that prior to marketing the patch, it had been studied on over 3,000 women.
See your doctor if you have experienced serious health problems after using the Ortho Evra patch. In addition, it may be important to contact an Ortho Evra lawyer who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.
Napoli Bern LLP
350 5th Avenue
Suite 7413
New York, NY 10118
Toll Free: 877 WTC HERO
Phone: 212 267 3700
Napoli Bern LLP
350 5th Avenue, Suite 7413,
New York, NY 10118
Toll Free: 1 888 LAW IN NY
Phone: 212 267 3700
New Jersey
1 Greentree Centre
Suite 201
Marlton, NJ 08053
New York
350 5th Avenue,
Suite 7413,
New York, NY 10118
3500 Sunrise Highway,
Suite T-207
Great River, NY 11739
Pennsylvania
2 Penn Center, Suite 200
Philadelphia, PA 19102
New York Defective Drugs and Medical Devices Lawyers
New York Auto Accident Lawyers
New York Construction and Jobsite Accident Lawyers
Marc Bern discusses the Diet Drug FenPhen on Geraldo
Marc Bern on CourtTV discussing Fen-Phen
Marc Bern is on Geraldo discussing the diet drug Fen-Phen
Trial Attorney Marc Bern discusses Breast Implants on Court TV
Marc Bern on CourtTV discussing breast implant litigation
Nancy Grace with Marc Bern about Jenny Jones Trial
New York Trial Attorney Marc Bern on Court TV
